Genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.
Both genes and environmental factors play a role in the occurrence of allergic diseases, according to a new study in Translational Pediatrics.
Genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.
Image credit: pingpao - stock.adobe.com
“Our prospective study found that a family history of allergy had no effects on [atopic dermatitis], allergic rhinitis, and wheezing between the twin groups,” wrote investigators, led by Jing Wang, from the department of pediatrics at Qilu Hospital of Shandong University in China. “Instead, environmental factors influenced the development of allergic diseases.”
The “allergic march” begins with infantile atopic dermatitis at 1 to 3 months of age. This is typically linked to food allergies, which progress during the first year of life. A prior birth cohort study found that infantile atopic dermatitis is associated with the development of asthma and rhinitis by 7 years old.
Investigators sought to understand the factors leading to the development of allergic diseases. They conducted a prospective clinical study of 80 identical and fraternal twins aged ≤ 4 years to identify the potential differences in environmental and genetic factors that contribute to allergy progression; data was collected via a 48-month questionnaire. In this study, identical and fraternal twins had similar rates of 60% to 80% for inhalation allergens at 2 years old.
The study reported no statistically significant differences between identical and fraternal twins in terms of gender, gestational age, history of asphyxia, feeding methods, and birth weight.
Compared with fraternal twins, identical twins had a significantly greater incidence of atopic dermatitis (100% vs 17%; P < .001), rhinitis (100% vs 20%; P < .001), and food allergy (100% vs 27%; P < .001). Wheezing had no significant difference in identical vs fraternal twins (80% vs 83%; P > .05).
Wang and colleagues discovered that, from 6 months to 48 months, the incidence of atopic dermatitis decreased (80% to 16.7% in identical twins; 50% to 26% in fraternal twins), and the incidence of rhinitis (5% to 16.7% in identical twins; 3% to 44% in fraternal twins) and wheezing (10% to 41.7% in identical twins; 0% to 26% in fraternal twins) increased.
Additionally, identical twins had a significantly greater consistency of inhaled allergens (100% vs 80%; P < .001; effect size, 0.619) and positive food allergens (86% vs 57%; P < .001; effect size, 0.597).
Investigators also analyzed the incidence of allergic diseases based on specific factors. For instance, among identical twins, they found atopic dermatitis and wheezing were more frequent in those who were male, had a birth weight of < 2500 g, and had another sibling (P < .05). Rhinitis in identical twins was more frequent among those who lived in a bungalow-style home, had pets, and had carpeting (P < .05).
As for fraternal twins, atopic dermatitis was more frequent in those who were born < 37 weeks gestation and had flowers or plants in the house (P < .05). Rhinitis in fraternal twins was more frequent in those born < 37 weeks gestation, with a history of neonatal asphyxia, and who lived in a smoking household (P < .05). Wheezing in fraternal twins was more frequent in those born < 37 weeks gestation, with a history of neonatal asphyxia, with central heating, and who lived in a smoking household (P < .05).
“The occurrence of allergic diseases in children is not only related to genes, but also influenced by environmental factors, and the influencing factors of allergic diseases in identical and fraternal twins are not the same,” investigators concluded.
References
Pediatric Food Allergy Diagnosis Could Be Streamlined By New Scoring System
May 10th 2025A newly developed Naples Pediatric Food Allergy grading scale, incorporating clinical history and examination, shows promise in streamlining the diagnosis of food allergies in children, potentially reducing delays and health care burdens.
Read More
Dupilumab Treatment for Patients With CSU: Insights From Jason Hawkes, MD, MS
April 29th 2025Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.
Read More
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More